EPISODE · May 20, 2026 · 3 MIN
Bea Biotech Brief — Regenxbio drops 43% despite positive DMD Phase III, DNA-guided CRISPR, and ASGCT's AAV-tumor warning
from Storyflo Daily
Welcome to Storyflo Daily Biotech. I'm Bea. The most-counterintuitive stock move of the week: per Genetic Engineering News, Regenxbio (NASDAQ: RGNX) shares nosedived 43% over two days late last week, reaching 52-week lows on consecutive sessions — despite generating positive pivotal Phase III data
Embed this episode
NOW PLAYING
Bea Biotech Brief — Regenxbio drops 43% despite positive DMD Phase III, DNA-guided CRISPR, and ASGCT's AAV-tumor warning
0:00
3:14
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Storyflo Daily?
This episode is 3 minutes long.
When was this Storyflo Daily episode published?
This episode was published on May 20, 2026.
Can I download this Storyflo Daily episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!